ERBB2 and breast cancer: Tucatinib, in combination with trastuzumab and capecitabine, significantly reduced the risk of intracranial progression and the risk of death in patients with brain metastases from HER2 + BC who were already receiving treatment in the HER2CLIMB trial (77).